Medicare Launches $50-a-Month GLP-1 Weight-Loss Coverage for Seniors

Medicare started covering weight-loss GLP-1 drugs for the first time on July 1, when the Centers for Medicare and Medicaid Services launched what it calls the Medicare GLP-1 Bridge. The program is narrow, temporary, and full of eligibility conditions that patients need to understand before they assume they qualify.

According to a program overview published by CMS, the Bridge runs from July 1, 2026, through December 31, 2027, and operates completely outside the standard Part D benefit. That last part is not a technicality, it has real consequences at the pharmacy counter. The $50 copay does not count toward a beneficiary's annual deductible or out-of-pocket cap, and Extra Help, the low-income subsidy that reduces costs for millions of Part D enrollees, cannot be applied to Bridge claims.

Three drugs are covered when prescribed strictly for weight management: Wegovy (semaglutide, both injection and tablet formulations), Zepbound (tirzepatide, but only the KwikPen formulation), and Foundayo (orforglipron, an oral option added to the program after its FDA approval in April 2026). The CMS provider guidance reviewed by ETL Newswire is explicit: if a prescription is written for the single-dose pen or single-dose vial of Zepbound rather than the KwikPen, the pharmacy claim will be rejected.

Clinical eligibility is based on BMI at the time GLP-1 therapy was first started, not necessarily today's BMI. According to CMS documentation, the three qualifying tiers are a BMI of 35 or higher; a BMI of 30 or higher with heart failure, uncontrolled hypertension, or chronic kidney disease; or a BMI of 27 or higher with pre-diabetes, a prior heart attack, stroke, or symptomatic peripheral artery disease. Patients already on GLP-1 therapy who have lost enough weight to fall below a threshold can still qualify if their prescriber retroactively attests to their BMI at the time of initial prescribing.

There is an important exclusion that will surprise some patients. Beneficiaries who already receive a GLP-1 drug through their Part D plan for type 2 diabetes, obstructive sleep apnea, or metabolic liver disease cannot use the Bridge. Those indications are already covered under standard Part D, and CMS says the Bridge is only for weight-management prescribing that current law bars Part D from covering.

Why does the law bar it? Federal statute has excluded weight-loss drugs from Part D since the program launched in 2006. Changing that requires congressional action. The Bridge exists because CMS found legal authority to run a payment demonstration outside the formal Part D coverage structure. CMS tapped Humana, which already runs the Low-Income Newly Eligible Transition program, as the central processor for prior authorizations, claims adjudication, and pharmacy payments.

The longer-term plan was a program called BALANCE, which was supposed to bring GLP-1 weight-loss coverage directly into Part D starting in 2027. CMS announced in May 2026 that the Part D component of BALANCE has been delayed indefinitely. The Bridge was extended through the end of 2027 to fill the gap, but as the Medicare Rights Center noted in its program analysis, what happens after December 31, 2027, is not settled.

For clinicians managing obesity medicine in a Medicare population, the administrative path is new territory. Prior authorization requests go to Humana's central processor, not to the patient's own plan. Plans don't need to opt in, and providers don't need Medicare enrollment to prescribe, but they must not appear on CMS's Preclusion List. The claim process is electronic only; paper claims won't be accepted.

The retail price of Wegovy without insurance runs well over $1,000 a month. For eligible patients, $50 is a real change. Whether the prior authorization process lives up to its design on the ground, and whether Congress ever makes the coverage permanent, are the questions worth watching.

Sources cited:
- CMS Medicare GLP-1 Bridge program page (https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge)
- CMS Information for Providers (https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers)
- CMS Information for Part D Plans (https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans)
- CMS Press Release, May 6, 2026 (https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries)
- Medicare Rights Center GLP-1 Bridge explainer (https://www.medicarerights.org/medicare-watch/2026/06/04/glp-1-weight-loss-drug-demonstration-begins-july-2026)